Doxorubicin (syn: Adriamycin) is the most extensively studied of a family of highly fluorescent anthracycline antibiotics produced by several Streptomyces species, first reported in 1967 and later approved for human therapeutic use as an antitumor agent for the treatment of a wide range of cancers. Doxorubicin also exhibits anti-HIV and antibacterial activity. The mode of action of doxorubicin is thought to be due to intercalation of DNA and inhibition of nucleic acid synthesis.
Doxorubicin is soluble in ethanol, methanol, DMF and DMSO.
|Mechanism of Action||Doxorubicin antimicrobial activity is thought to be due to intercalation of DNA and inhibition of nucleic acid synthesis.|
|References||Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic. Arcamone F. et al. , Tet. Letters 1969, 13, 1007.
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Fornari F.L. et al. , Mol. Pharmacology 1994, 45, 649.
Effect of Adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Momarier R. et al. , Cancer Research 1976, 36, 2891.